182 related articles for article (PubMed ID: 18442220)
21. The effect of proton pump inhibitors on the CYP2C19 enzyme activity evaluated by the pantoprazole-
Modak AS; Klyarytska I; Kriviy V; Tsapyak T; Rabotyagova Y
J Breath Res; 2016 Dec; 10(4):046017. PubMed ID: 27991432
[TBL] [Abstract][Full Text] [Related]
22. Rabeprazole for the treatment of acid-related disorders.
Marelli S; Pace F
Expert Rev Gastroenterol Hepatol; 2012 Aug; 6(4):423-35. PubMed ID: 22928894
[TBL] [Abstract][Full Text] [Related]
23. [New-generation proton pump inhibitors: progress in the treatment of peptic acid diseases?].
de Korwin JD; Ducrotté P; Vallot T
Presse Med; 2004 Jun; 33(11):746-54. PubMed ID: 15257232
[TBL] [Abstract][Full Text] [Related]
24. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
25. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
26. Formulary management of proton pump inhibitors.
Byrne MF; Murray FE
Pharmacoeconomics; 1999 Sep; 16(3):225-46. PubMed ID: 10558037
[TBL] [Abstract][Full Text] [Related]
27. Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.
Dash RP; Rais R; Srinivas NR
Xenobiotica; 2018 Apr; 48(4):422-432. PubMed ID: 28294690
[TBL] [Abstract][Full Text] [Related]
28. [Clinical pharmacological aspects of the proton pump inhibitor therapy: importance of pharmacogenetic differences in the clinical practice].
Mullner K; Molnar B; Tulassay Z
Orv Hetil; 2007 Mar; 148(12):543-51. PubMed ID: 17444020
[TBL] [Abstract][Full Text] [Related]
29. [Factors affecting efficacy of gastroesophageal reflux disease treatment with proton pump inhibitors].
Ter Arkh; 2012; 84(2):16-21. PubMed ID: 22715656
[TBL] [Abstract][Full Text] [Related]
30. Systematic review: proton pump inhibitors (PPIs) for the healing of reflux oesophagitis - a comparison of esomeprazole with other PPIs.
Edwards SJ; Lind T; Lundell L
Aliment Pharmacol Ther; 2006 Sep; 24(5):743-50. PubMed ID: 16918878
[TBL] [Abstract][Full Text] [Related]
31. Pantoprazole: from drug metabolism to clinical relevance.
Bardou M; Martin J
Expert Opin Drug Metab Toxicol; 2008 Apr; 4(4):471-83. PubMed ID: 18433349
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness comparison of current proton-pump inhibitors to treat gastro-oesophageal reflux disease in the UK.
Remák E; Brown RE; Yuen C; Robinson A
Curr Med Res Opin; 2005 Oct; 21(10):1505-17. PubMed ID: 16238890
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
34. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.
Röhss K; Lind T; Wilder-Smith C
Eur J Clin Pharmacol; 2004 Oct; 60(8):531-9. PubMed ID: 15349707
[TBL] [Abstract][Full Text] [Related]
35. [How to choose correct proton pump inhibitors to patients with GERD?].
Bordin DS
Eksp Klin Gastroenterol; 2010; (2):53-8. PubMed ID: 20496811
[TBL] [Abstract][Full Text] [Related]
36. Inappropriate use of proton pump inhibitors.
Molloy D; Molloy A; O'Loughlin C; Falconer M; Hennessy M
Ir J Med Sci; 2010 Mar; 179(1):73-5. PubMed ID: 19763673
[TBL] [Abstract][Full Text] [Related]
37. Chiral separation in the class of proton pump inhibitors by chromatographic and electromigration techniques: An overview.
Papp LA; Hancu G; Kelemen H; Tóth G
Electrophoresis; 2021 Sep; 42(17-18):1761-1789. PubMed ID: 34004039
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of proton-pump inhibitors for maintenance therapy of erosive reflux esophagitis.
Dean BB; Siddique RM; Yamashita BD; Bhattacharjya AS; Ofman JJ
Am J Health Syst Pharm; 2001 Jul; 58(14):1338-46. PubMed ID: 11471482
[TBL] [Abstract][Full Text] [Related]
39. Ten mg dexrabeprazole daily is as effective as 20 mg rabeprazole daily.
Kanakia R; Jain S
World J Gastroenterol; 2008 Jul; 14(28):4586-7. PubMed ID: 18680246
[TBL] [Abstract][Full Text] [Related]
40. The use of proton pump inhibitors in children: a comprehensive review.
Gibbons TE; Gold BD
Paediatr Drugs; 2003; 5(1):25-40. PubMed ID: 12513104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]